Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DateTimeSourceHeadlineSymbolCompany
24/01/202521:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
16/01/202521:15Business WireSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SMMTSummit Therapeutics Inc
14/01/202521:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SMMTSummit Therapeutics Inc
13/01/202513:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
07/01/202512:00Business WireSummit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
07/01/202500:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SMMTSummit Therapeutics Inc
07/01/202500:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SMMTSummit Therapeutics Inc
13/12/202421:15Business WireSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SMMTSummit Therapeutics Inc
26/11/202421:15Business WireSummit Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:SMMTSummit Therapeutics Inc
21/11/202421:15Business WireSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SMMTSummit Therapeutics Inc
30/10/202411:33Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SMMTSummit Therapeutics Inc
30/10/202411:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
30/10/202411:00Business WireSummit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024NASDAQ:SMMTSummit Therapeutics Inc
23/10/202420:15Business WireSummit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024NASDAQ:SMMTSummit Therapeutics Inc
04/10/202420:15Business WireSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SMMTSummit Therapeutics Inc
03/10/202420:15Business WireSummit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLCNASDAQ:SMMTSummit Therapeutics Inc
19/09/202421:28Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:SMMTSummit Therapeutics Inc
16/09/202410:30Business WirePromising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024NASDAQ:SMMTSummit Therapeutics Inc
13/09/202421:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SMMTSummit Therapeutics Inc
12/09/202410:49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
12/09/202410:49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
12/09/202410:30Business WireSummit Therapeutics Raises $235 MillionNASDAQ:SMMTSummit Therapeutics Inc
09/09/202411:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
08/09/202415:45Business WireIvonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in ChinaNASDAQ:SMMTSummit Therapeutics Inc
06/09/202420:15Business WireSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SMMTSummit Therapeutics Inc
12/08/202411:00Business WireHARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024NASDAQ:SMMTSummit Therapeutics Inc
11/08/202423:30PR Newswire (US)Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024NASDAQ:SMMTSummit Therapeutics Inc
09/08/202420:15Business WireSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SMMTSummit Therapeutics Inc
06/08/202413:03Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:SMMTSummit Therapeutics Inc
06/08/202411:37Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT